COPD
Conditions
Interventions
None listed
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: a. >= 40 years b. Smoking history >=10 pack years c. COPD patients (GOLD stage II-IV) according to GOLD guidelines d. Meeting the criteria for an exacerbation at inclusion
Exclusion criteria
Exclusion criteria: • History of other pulmonary disease • Systemic steroid or antibiotic therapy for > 24 hours
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Part I Breathprints obtained by SpiroNose of patients during an exacerbation of COPD with or without bacterial infection. Bacterial infection will be defined as colony-forming units >107/mL sputum or >105/mL in S. pneumonia [36]. Part II Changes in breathprints obtained by SpiroNose of patients during exacerbation and recovery with or without viral, bacterial, viral and bacterial, or absence of infection. A virus was deemed present when either the sputum or naso-pharyngeal swap tested positive by PCR [31]. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary study parameters (part I and II): • Specific molecular components (VOCs), which are, associated with the different origins of exacerbation of COPD patients as determined by gas- chromatography and mass-spectrometry (GC-MS). We will determine: retention time, abundance and the mass-to-charge ratio. • Individual cellular and molecular biomarkers in sputum and blood. We will determine CRP, a complete blood count including differentiation, inflammatory markers, cytokines and chemokines. | — |
Countries
Netherlands
Outcome results
None listed